Brief: Tiziana Life Sciences Announces FDA Ind Clearance Of Intranasal Foralumab For The Treatment Of Alzheimer’S Disease
15/08/2023 12:32
Tiziana Life Sciences Ltd TLSA.O :
* TIZIANA LIFE SCIENCES ANNOUNCES FDA IND CLEARANCE OF
INTRANASAL
FORALUMAB FOR THE TREATMENT OF ALZHEIMER’S DISEASE
* TIZIANA LIFE SCIENCES: FORALUMAB TO ADVANCE INTO PHASE 2
HUMAN
CLINICAL TRIALS USING WORLD'S ONLY FULLY HUMAN INTRANASAL
ANTI-CD3 MONOCLONAL ANTIBODY
* TIZIANA LIFE SCIENCES LTD: TRIAL TO BE OVERSEEN BY BRIGHAM
AND
WOMEN'S HOSPITAL, A FOUNDING MEMBER OF MASS GENERAL BRIGHAM
HEALTHCARE SYSTEM
Source text for Eikon: ID:nGNX9YVpWq
Further company coverage: TLSA.O
Recent news on Tiziana Life Sciences
See all newsBrief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis
U.S. STOCKS ON THE MOVE -Viatris, Clear Secure, Bicara
U.S. STOCKS ON THE MOVE-Sharps Technology, Whirlpool, Applovin
U.S. STOCKS ON THE MOVE-Oracle, Vanda, Keysight
Tiziana Life Sciences rises as nasal MS drug shows promise in early study